In Brief: Regulatory reform
This article was originally published in The Gray Sheet
Regulatory reform: Legislation may be taken up on the Senate floor as early as the week of June 19, Hill staffers indicate. A bipartisan group has been preparing a compromise version of regulatory reform legislation since mid-May. The compromise bill is understood to contain portions of other regulatory reform bills under consideration in the Senate, including bills introduced by Government Affairs Committee Chairman Sen. William Roth (R-Delaware) and Sen. Robert Dole (R-Kansas). Floor debate is expected to center on the bill's provisions regarding regulatory risk assessment, judicial review and the repeal of the Delaney Clause's de minimus standard for carcinogenic agents...
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.